middle.news
Zelira Strengthens Capital and Advances FDA Trials with New Funding Moves
11:06am on Tuesday 29th of April, 2025 AEST
•
Biotechnology
Read Story
Zelira Strengthens Capital and Advances FDA Trials with New Funding Moves
11:06am on Tuesday 29th of April, 2025 AEST
Key Points
Received $1.15 million R&D tax incentive refund
Established $1 million At-the-Market equity facility for flexible capital
Completed full conversion of US$3.25 million convertible notes into HOPE® 1 SPV equity
Capsule formulation development for HOPE® and Zenivol® on track for mid to late 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Zelira Therapeutics (ASX:ZLD)
OPEN ARTICLE